Camizestrant

N/A

Report date: 2026/02/25 20:02:36
NME

Base Information

Drug NameCamizestrant
Drug Alias NameAZD-9833AZ-14066724
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEstrogen receptors degraders
TargetsEstrogen receptors
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursHepatic Insufficiency +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[53] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbAstrazeneca Investment (China) Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursHepatic Insufficiency +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A